Error loading player: No playable sources found

Plenary Session 3 - Navigating the Regulatory Landscape: Global Convergence and Innovation in Biopharmaceutical Manufacturing

Date
January 28, 2025
This product is not available for individual purchase, but it is available as part of the following products:

In this session, regulatory leaders from the EMA, Health Canada, PMDA, Health Canada, and international health authorities including WHO will delve into the challenges hindering the path to regulatory reliance and approval of advanced technologies. By sharing their insights and experiences, they will illuminate potential solutions to overcome these obstacles and accelerate the journey towards a unified "One Submission/One inspection/One Assessment" approach. 

Join us as we explore the latest advancements in technology and reliance that are reshaping the regulatory landscape. Together, we can foster a collaborative environment that benefits all companies and countries. 

Ahead of and during the session, we invite attendees to share their most pressing challenges and transformative solutions. Your contributions will help shape a more productive and insightful discussion. 

Key Highlights: 

- Regulatory Reliance Progress: Are recent advancements in reliance tools and pilots being shared across all regions and companies? 

- Future of Biopharmaceutical Manufacturing: What does the future hold for biopharmaceutical manufacturing, and how can regulators support these changes? 

- Advanced Technologies: How are regulators incorporating advancements in technology to improve efficiency and speed to patient? 

- Global Convergence: What steps can be taken to promote greater convergence and collaboration among regulatory authorities? 



Session Panelists:


Rogério Gaspar, World Health Organization


Yasuhiro Kishioka, Pharmaceuticals and Medical Devices Agency (PMDA)


Anabela Marçal, European Medicines Agency (EMA)


Claudia Müller, Swissmedic


Sophie Sommerer, Health Canada


Related Products

Thumbnail for Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
The pharmaceutical industry is increasingly viewed as a key sector systemically important in reversing nature loss.     One of the sector’s key dependencies is on the horseshoe crab , a species that is vital to marine ecosystems only located in a few locations globally…
Thumbnail for Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Potency analytical control strategies are critical to support biopharmaceutical drug and vaccine development throughout the product lifecycle…
Thumbnail for Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Monitoring and control of endotoxin are critical aspects of an overall microbial control strategy necessary to ensure drug product quality and patient safety…